

May 7, 2024  
SymBio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer  
(Securities Code: 4582)

## Revision to Earnings Forecast for FY 2024

TOKYO, Japan, May 7, 2024 – SymBio Pharmaceuticals Limited (Headquarters: Tokyo, “SymBio” or the “Company”) today announced that the Company’s Board of Directors today approved the following revision to the earnings forecast for fiscal year ending December 31, 2024. The earnings forecast was previously announced on December 8, 2023. The revision reflects the Company’s current performance trends and outlook.

### 1. Revision to Earnings Forecast for FY 2024 (January 1, 2024 to December 31, 2024)

	Net Sales	Operating Profit	Ordinary Profit	Profit attributable to owners of parent	Earnings per share
	Yen millions	Yen millions	Yen millions	Yen millions	Yen
Previous Forecast (A)	3,641	(2,837)	(2,867)	(2,870)	(71.93)
Revised Forecast (B)	2,623	(3,702)	(3,524)	(3,628)	(84.15)
Difference (B-A)	(1,018)	(865)	(657)	(758)	—
Percentage Change (%)	(28.0)	(30.5)	(22.9)	(26.4)	—
[Reference] Prior Year Results (FY 2022)	5,589	(811)	(736)	(1,962)	(49.19)

### 2. Reasons for changes

The NHI price of TREAKISYM® has declined due to a reduction in the premium for new drug creation following the launch of generic drug products. As a result, sales in the first quarter were lower than expected due to the impact of inventory adjustments prior to the application of the new drug price which became effective in April 2024.

A downward trend in prescriptions per case of malignant lymphoma due to the epidemic in infectious diseases is expected to continue, and the market share of generic drug products is expected to gradually increase going forward. As it is expected to be difficult to recover the sales decline of the first quarter from the second quarter onward, the Company has lowered its sales forecast for the fiscal year ending

December 31, 2024, by 1,018 million yen (a decrease of 28.0%) to 2,623 million yen.

Although R&D expenses are expected to be 3,409 million yen (up 201 million yen from the previous forecast) due to steady progress in clinical trials, selling, general and administrative expenses were generally in line with the forecast due to a review of other expenses. As a result of the impact of the significant decrease in gross profit due to the decline in net sales, the Company has revised its forecasts for operating loss of 3,702 million yen (a reduction of 865 million yen compared to the previous forecast), ordinary loss of 3,524 million yen (a reduction of 657 million yen compared to the previous forecast), and net loss attributable to owners of the parent of 3,628 million yen (a reduction of 758 million yen compared to the previous forecast).

The assumption of the foreign exchange rate has been changed from 141.83 yen per U.S. dollar to 151.41 yen per U.S. dollar.

\*Earnings forecasts, financial projections, and other forecasts or forward-looking statements contained in this disclosure have been prepared by the Company at its discretion and based on information available to the Company as of the date of this disclosure. Actual results may vary materially from the information contained in this disclosure as a result of changes to business, economic, financial, or other assumptions and conditions.

**[Contact]**

Investor Relations

Tel: +81(0)3 5472 1125